Mary K. Moreland - Feb 18, 2022 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Mary K. Moreland by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Feb 18, 2022
Transactions value $
-$140,337
Form type
4
Date filed
2/23/2022, 07:23 PM
Previous filing
Aug 3, 2021
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +15.8K +21.86% $0.00 88.2K Feb 18, 2022 Direct F1
transaction ABT Common shares without par value Tax liability -$92.6K -793 -0.9% $116.79 87.4K Feb 22, 2022 Direct
transaction ABT Common shares without par value Sale -$47.7K -400 -0.46% $119.31 87K Feb 22, 2021 Direct F2
holding ABT Common shares without par value 11K Feb 18, 2022 Profit Sharing Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +73.7K $0.00 73.7K Feb 18, 2022 Common Shares 73.7K $117.58 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.3003 to $119.3100, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 Balance in the Abbott Laboratories Stock Retirement Trust as of February 18, 2022.
F4 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,565 on February 18, 2023, 24,565 on February 18, 2024, and 24,566 on February 18, 2025.

Remarks:

The sale transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1(c).